National Research Center for Hematology, Russia

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)

Phase 2

Active, not recruiting

Conditions: Chronic Myeloid Leukemia
Chronic Myeloid Leukemia in Remission
BCR-ABL Positive Chronic Myelogenous Leukemia

Interventions: Drug: Imatinib
Drug: Nilotinib
Drug: Dasatinib
Drug: Bosutinib

First Posted Date: 2020-10-08

Last Posted Date: 2020-10-08

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 100

Registration Number: NCT04578847

Locations: 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation

Registry of Patients With Hematologic Disease and COVID-19 in Russia

Completed

Conditions: Coronavirus Infection and Hematologic Diseases

First Posted Date: 2020-06-09

Last Posted Date: 2023-01-26

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 666

Registration Number: NCT04422470

Locations: 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation
🇷🇺
RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, Saint Petersburg, Russian Federation
🇷🇺
Regional Clinical Hospital No1, Ekaterinburg, Russian Federation

and more 10 locations

De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)

Not Applicable

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions: Procedure: Autologous HSCT

First Posted Date: 2018-03-12

Last Posted Date: 2018-03-13

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 350

Registration Number: NCT03462095

Locations: 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation

Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT

Phase 3

Conditions: Mesenchymal Stem Cell Transplantation

First Posted Date: 2018-01-04

Last Posted Date: 2018-01-04

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 20

Registration Number: NCT03389919

Locations: 🇷🇺
BMT department, Moscow, Russian Federation

R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis

Phase 3

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: R-mNHL-BFM-90
Drug: R-DA-EPOCH-21
Drug: R-DA-EPOCH-21 + auto-SCT
Drug: R-mNHL-BFM-90 + auto-SCT

First Posted Date: 2016-07-25

Last Posted Date: 2016-07-25

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 300

Registration Number: NCT02842931

Locations: 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation

Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma

Phase 3

Conditions: Follicular Lymphoma

First Posted Date: 2015-04-22

Last Posted Date: 2015-04-22

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 200

Registration Number: NCT02423837

Locations: 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation

MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis

Phase 2

Conditions: Leukemia
Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Biological: Mesenchymal stromal cells

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 40

Registration Number: NCT02270307

Locations: 🇷🇺
BMT department, Moscow, Russian Federation

Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation

Phase 2

Conditions: Graft-versus-host Disease
Relapse

Interventions: Biological: Mesenchymal stem cells

First Posted Date: 2013-09-13

Last Posted Date: 2013-09-13

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 70

Registration Number: NCT01941394

Locations: 🇷🇺
BMT department, Moscow, Russian Federation

Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia

Phase 1

Conditions: Septic Shock
Nonchemotherapy Drug-induced Neutropenia
Neutropenia After Chemotherapy in Oncohematological Patients
Neutropenia in Patients With Aplastic Anemia

Interventions: Drug: Standard therapy of septic shock
Genetic: Mesenchymal stromal cells

First Posted Date: 2013-05-08

Last Posted Date: 2013-05-10

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 30

Registration Number: NCT01849237

Locations: 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation

3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia

Phase 4

Conditions: Acute Myeloid Leukemia

Interventions: Drug: high dose ARA-C
Drug: standard dose ARA-C

First Posted Date: 2012-04-30

Last Posted Date: 2014-04-07

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 245

Registration Number: NCT01587430

Locations: 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy